As expected, the FDA approves Johnson & Johnson (NYSE:JNJ) unit Janssen Pharmaceutical's SPRAVATO (esketamine) CIII nasal spray, together with an oral antidepressant, for adults with treatment-resistant depression.

Almost a month ago, an FDA advisory committee voted 14 - 2 in favor of approval.

READ FULL ARTICLE HERE